Clinical Trials Search Results

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome

Phase I Trial with Expansion Cohort of Obp-301 (Telomelysintm) And Definitive Chemoradiation For Patients with Locally Advanced Esophageal And Gastroesophageal Adenocarcinoma Who Are Not Candidates For Surgery

A Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia

A Proof of Concept Study of TBio-4101 (an Autologous selected and expanded tumor infiltrating lymphocyte [TIL] therapy) Using Short-Term Cultured, Selected Autologous TIL following a Lymphodepleting Chemotherapy Regimen and Followed by IL-2 for Patients with Relapsed or Refractory Solid Tumors (Phase 1)

A Phase II Study of Cemiplimab plus Ziv-Aflibercept for Subjects with Metastatic Uveal Melanoma

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors

A Phase 1b/3 Double-Blind, Randomized,Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma

A Phase IIa Study of Dendritic Cell Vaccines against HER2/HER3 and Pembrolizumab in Patients with Asymptomatic Brain Metastasis from Triple Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)

A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib In Refractory Advanced Thymic Carcinoma

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC